Caterina Lamanna

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial

Olga Vaccaro, Maria Masulli, Antonio Nicolucci et al. · The Lancet Diabetes & Endocrinology · 2017 · 285 citations

Diabetes Management, Cardiovascular Disease, Diabetes +9

Sulphonylureas and cancer: a case–control study

Matteo Monami, Caterina Lamanna, Daniela Balzi et al. · Acta Diabetologica · 2008 · 190 citations · Full text

Case–control Study, Medicine, Pathology +3

Liver enzymes and risk of diabetes and cardiovascular disease: Results of the Firenze Bagno a Ripoli (FIBAR) study

Matteo Monami, Gianluca Bardini, Caterina Lamanna et al. · Metabolism · 2008 · 129 citations

Firenze Bagno, Fatty Liver Disease, Oxidative Stress +16

Three‐year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin

Matteo Monami, Chiara Luzzi, Caterina Lamanna et al. · Diabetes/Metabolism Research and Reviews · 2006 · 113 citations

Doses of Insulin and Its Analogues and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients

Edoardo Mannucci, Matteo Monami, Daniela Balzi et al. · Diabetes Care · 2010 · 113 citations · Full text